Genetically modified dendritic cells (DC) constitute a promising approach in cancer immunotherapy. Viral gene delivery systems have been shown to be very efficient strategies, but safety concerns for their clinical use in immunotherapy remain an important issue. Recently, the technique of mRNA electroporation was described as a very efficient tool for the genetic modification of human monocyte-derived DC. Here, we show that transgene expression can be modulated by varying the amount of mRNA used for electroporation. We document that CD40 ligation leads to a significant production of IL-12 by the electroporated DC, although the level of IL-12 production is somewhat lower than for non-or mock-electroporated DC. Furthermore, we show that the electroporated DC can be frozen and thawed without loss of viability or function and that Influenza virus Matrix Protein 1 mRNA electroporated DC are capable of inducing a memory cytotoxic T lymphocyte response and are more potent in doing so than mRNA-pulsed DC. Similar results were obtained with MelanA/MART-1 mRNA electroporated DC. These results clearly indicate that mRNA-electroporated DC represent powerful candidates for use as tumor vaccines and could constitute an improvement compared with vaccines using peptide-pulsed DC.
D
endritic cells (DC) are considered to be the most potent antigen presenting cells of the immune system. In an immature stage, DC are present in every tissue and specialized in internalizing and processing antigens. These cells are very sensitive to ''danger signals'' in response to which they migrate to lymphoid organs and undergo maturation. During maturation, DC upregulate costimulatory molecules (CD80, CD86), chemokine receptors and DC-specific markers (CD83, DC-LAMP). These mature DC (mDC) are fully equipped to present antigenic epitopes to CD4 + and CD8 + T lymphocytes in order to induce an antigen-specific T-cell response. As a consequence, the use of DC is a promising approach in immunotherapy for cancer and infectious diseases. [1] [2] [3] [4] [5] [6] Many different methods have been used to load DC with antigens before in vivo injection. Protein-or peptidepulsed DC have been shown to be potent inducers of antigen-specific antitumor responses both in a variety of experimental animal models and in cancer patients. [7] [8] [9] [10] However, the proteins corresponding to tumor-associated antigens (TAA) are thus far seldom available. Synthetic peptides corresponding to the TAA epitopes recognized in the context of particular MHC class I molecules or acideluted tumor peptides can be used to load DC. However, these peptide-based strategies may have some drawbacks, such as the transient presentation of the antigenic epitopes to the T cells due to the rapid turnover of the preformed peptide/MHC complexes, the variability of the binding affinities of the synthetic peptides and the presence of cellbound peptidases. The use of peptides also relies on the knowledge of the MHC haplotype of each patient and the corresponding class I binding motifs of the TAA. 11 Moreover, while the peptide motifs for MHC class I presentation are relatively well known, the sequences necessary to load MHC class II molecules are not as well defined. The lack of antigen-specific help for the induction of cytotoxic T-cell responses might result in a less efficient or suboptimal immune response. [12] [13] [14] [15] [16] In an attempt to optimize the use of DC to induce an antitumor response we have focused on a strategy allowing the expression of the entire tumor antigen polypeptide in DC. Genetic modification of DC has a number of potential advantages to peptide-or proteinbased methods. Genetic modification does not require the prior knowledge of the HLA haplotype of the patients nor of the particular TAA peptides binding to the restriction elements. In addition, multiple and not yet defined peptide epitopes encoded by the whole tumor antigen polypeptide might contribute to T-cell activation.
Another advantage of genetic modification of DC is that one can modify the TAA with targeting signals to obtain better MHC class I and class II presentation. Incorporation of ubiquitin will result in an enhanced formation of peptides for MHC class I presentation, [17] [18] [19] whereas targeting sequences from the invariant chain (Ii) or lysosome-associated membrane protein (Lamp1) will lead to presentation of the antigen in the context of both MHC class I and class II, thus providing antigen-specific help. [20] [21] [22] [23] Several strategies have been explored to deliver genes into DC. They can be divided into two groups: viral and nonviral strategies. Viral gene delivery systems are generally more efficient compared to nonviral systems, but safety concerns about their use for clinical applications, the production of ''clinical-grade'' viral stocks and the potential boosting of antivirus responses remain major obstacles. [24] [25] [26] [27] Among the numerous nonviral methods to genetically modify DC, we mention the pulsing of DC with naked RNA or plasmid DNA and lipofection of RNA or DNA. [28] [29] [30] [31] [32] [33] [34] [35] [36] The different methods can either use the full antigenic spectrum of the tumor or can focus on only one TAA. The former strategy is believed to be more effective in eradicating the tumor, because of a reduced risk that antigen-loss variants will arise and escape the immune response. On the other hand, when the full antigenic spectrum of the tumor cells is used, the risk to induce auto-immunity has to be considered.
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In this study, we further characterize mRNA-electroporated DC. Previous reports described that mRNA electroporation does not influence DC viability, DC phenotype or allo-stimulatory capacity. 34, [36] [37] [38] We show that the transgene expression level can be modulated by varying the amount of mRNA used for electroporation. mRNA-electroporated DC can respond to CD40 ligation by IL-12 secretion, albeit slightly reduced compared to non-or mock-electroporated DC. We demonstrate that influenza matrix protein 1 (IMP-1) electroporated DC are able to induce a memory cytotoxic T lymphocyte (CTL) response against the influenza matrix peptide and that the expression level of the transgene correlates with the potency of the CTL response. In addition, we are able to induce MelanA-specific T lymphocytes by stimulation with MelanA/MART-1 mRNA electroporated DC. In view of clinical trials, we upscaled the electroporation protocol in order to minimize manipulations. We also show that mature, electroporated DC can be efficiently cryopreserved, without effect on viability, phenotype or ability to induce an antigen-specific immune response.
Materials and methods

Synthetic peptides
The influenza virus matrix protein 1 derived HLA-A2 restricted peptide (IMP-1-A2) (GILGFVFTL; amino acids 58-66) was purchased from Eurogentec (Seraing, Belgium), dissolved in DMSO (2 mg/ml) and stored at À201C.
The MelanA/MART-1 derived HLA-A2 restricted peptide (MelanA-A2) (EAAGIGILTV; amino acids 26-35) was a kind gift from Dr P van der Bruggen (Ludwig Institute, Brussels, Belgium) and was dissolved in DMSO (2 mg/ml) and stored at -201C.
b2 microglobulin was purchased from Calbiochem (Darmstadt, Germany), dissolved in PBS (250 mg/ml) and stored at -201C.
Cell lines and clones
3T6 cells and 3T6 cells transfected with the human CD40Ligand (3T6-hCD40L) were cultured in RPMI1640 (Cambrex, Verviers, Belgium) medium supplemented with 10% fetal calf serum (FCS), 100 U/ml penicillin, 100 mg/ ml streptomycin (P/S) and 2 mM l-glutamine. Additionally, 200 mg/ml G418 was added to the 3T6-hCD40L cells to select transfected cells.
T2 cells were cultured in RPMI1640 medium supplemented with 10% FCS, P/S, 0.55 mM l -arginine, 0.24 mM l -asparagine and l -glutamine (AAG).
Plasmids
The vector pGEM4Z/eGFP/64A was kindly provided by Dr E Gilboa (Duke University Medical Center, Durham, NC, USA). This plasmid contains a 741 bp eGFP fragment from peGFP-N1 (Clontech, CA, USA), flanked by the 5 0 and 3 0 UTRs of Xenopus laevis beta-globin, and 64 A-T bp. Transcription is controlled by a bacteriophage T7 promoter. SpeI and NotI sites are present at the 3 0 end of the A64 stretch to allow linearization of the plasmid before in vitro transcription.
Ubiquitin was amplified from C57BL/6 mouse cDNA using the following primers:
0 . This PCR again adds on NcoI site spanning the start codon and a BamHI sites at the 3 0 end. The truncated human nerve growth factor receptor (extracellular and transmembrane fragment) cDNA was amplified from the plasmid ptNGFR kindly provided by Dr C Traversari (Instituto Scientifico HSRaffaele, Milan, Italy). The primers used for PCR were: 5 0 CCCTCAT GA BspHI GGGCAGGTGCCACCG3 0 and 5 0 GGGAGAT CT BglII CTAGAGGATCCCCCTCTTCC3 0 . During the PCR, a 5 0 BspHI site, spanning the start codon, a stop codon and a BglII site at the 3 0 end were inserted. The eGFP gene was excised from pGEM-5 0 UT-eGFP-3 0 UT-A64 with NcoI and BamHI and replaced with a BspHIBglII fragment containing the tNGFR gene or an NcoI-BamHI ubiquitin fragment.
The IMP-1 (A/PR/8/34) gene fragment was amplified from the plasmid pIMP, purchased from LMBP (Laboratory of Molecular Biology Plasmid collection, University of Ghent, Belgium). The gene was amplified in two segments in order to omit the nuclear localization signal (RKLKR, position 301-305). The following primers were used: IMP-1S1 5 0 GGGAGATCT BglII CAGTCTTCTAAC 
In vitro transcription of RNA
Prior to in vitro transcription, the plasmids pGEM4Z/ eGFP/64A and pGEM4Z/MelanA/64A were linearized with SpeI and the plasmids pGEM4Z/NGFR/64A and pGEM4Z/ubi.IMP-1/64A were linearized with NotI. The in vitro RNA transcription was performed with T7 RNA polymerase (Ambion mMESSAGE mMACHINEt kit, Austin, TX, USA). The transcribed RNA was recovered after DNaseI digestion and LiCl precipitation according to the manufacturer's instructions. mRNA quality was verified by agarose gel electrophoresis and RNA concentration was measured spectrophotometrically.
Generation of monocyte-derived dendritic cells
As a source of peripheral blood mononuclear cells (PBMC), either buffy coats or leukapheresis products from healthy donors were used. When using buffy coats, PBMC were isolated through a Lymphoprep NYCOMEDt (1077 g/ml; Invitrogen, Merelbeke, Belgium) density centrifugation. For DC generation, procedures previously described by Romani et al were followed with minor modifications to increase DC yield. Briefly, 220 Â 10 6 PBMC were plated per T175 cm 2 flask in 45 ml X-VIVO-15 medium (Cambrex) supplemented with 1% heat-inactivated human AB serum (PAA Laboratories, Linz, Austria) (X-15/1%HuAB medium) or with 1% heat-inactivated autologous plasma (X-15/1%AP medium) for 2 hours to allow plastic adherence of monocytes. Nonadherent cells were removed by washing and adherent cells were further cultured for 6 days in 45 ml X-15/1%HuAB medium or X-15/1%AP medium supplemented with 800 U/ml GM-CSF (Leucomax, Novartis, Basel, Switzerland) and 100 U/ml IL-4 (homemade as described previously). 39 A volume of 7 ml of medium containing the cytokine amount of day 0 was added on days 2 and 4 of culture. On day 6, cells were harvested and either non-, mock-or RNA-electroporated. Immediately after transfection, cells were resuspended at 250 Â 10 3 DC/ml in X-15/1%HuAB medium supplemented with a maturation cocktail consisting of 1000 U/ml GM-CSF, 100 U/ml IL-4, 1000 U/ml IL-6 (PeproTech, London,UK),10 ng/mlIL-1b(PeproTech),100 U/mlTNFa (PeproTech) and 1 mg/ml PGE 2 (Sigma-Aldrich, Bornem, Belgium) for 24, 48 or 72 hours (as indicated). When using leukapheresis products, PBMC isolation and DC production were performed according to our previously described method. 39 mRNA pulsing of DC Two different cell densities were used. DC were washed once with serum-free culture medium, resuspended at 10 6 cells/ml in serum-free X-15 medium and incubated for 45 minutes in the presence of 1.5 mg/ml mRNA in a humidified incubator at 371C/5% CO 2 . RNA-pulsed DC were washed once before the maturation medium was added (protocol 1 according to Gilboa et al). 40 Alternatively, DC were washed once with serum-free culture medium, resuspended at 40 Â 10 6 cells/ml in serum-free X-15 medium and exposed for 15 minutes to 100 mg/ml mRNA at room temperature. Then the maturation medium was added. This latter protocol 2 mimics the conditions as during the electroporation method.
mRNA electroporation of DC DC were electroporated on day 6 of the culture. Two electroporation media were compared: serum-free X-15 culture medium (without additives) and Optimix buffer (EQUIBIO, Kent, UK), an optimized eucaryotic cell electroporation buffer. DC were harvested and washed twice in serum-free X-15. When Optimix buffer was used, DC were washed once in serum-free X-15 and once in the Optimix solution A. In both cases, volumes were adjusted to reach a final cell density of 20 Â 10 6 or 40 Â 10 6 DC/ml and mixed at RT with 20 mg RNA in a final volume of 200 ml, either in X-15 or Optimix buffer. Electroporation of 12 Â 10 6 DC occurred at a cell density of 60 Â 10 6 cells/ ml with 30 mg RNA in 200 ml and electroporation of 50 Â 10 6 DC occurred at 83 Â 10 6 cells/ml in 600 ml. The cell suspension was transferred to a 4-mm gap electroporation cuvette for immediate electroporation using the EQUIBIO EasyjecT Plus s apparatus (EQUIBIO). Electroporation conditions were as follows: voltage of 300 V, capacitance of 150 mF, resistance of 99 O resulting in a pulse time of 5-6 ms. Electroporation of 50 Â 10 6 DC occurred in 600 ml and parameters were adjusted as follows: 300 V, 450 mF and 99 O. Cells were immediately diluted in prewarmed maturation medium.
Peptide pulsing of DC mDC were loaded at a cell density of 2 Â 10 6 DC/ml in DMEM (Cambrex) with 10 mg/ml of the indicated peptide and 2.5 mg/ml of b2 microglobulin during 1 hour at 371C. Prior to use, the DC were washed twice in DMEM and subsequently resuspended in the appropriate medium.
Purification of DC
Two different approaches were used to separate the DC from contaminating lymphocytes. Day 6 immature DC (iDC) were further enriched using anti-CD3 (clone 4 stimulator DC were separately cultured in medium. Cells were harvested on glass filter paper and isotope incorporation was measured by scintillation counting. The stimulation index was calculated as the number of counts of the coculture minus the number of counts of DC alone, divided by the number of counts of the T cells alone.
IL-12 secretion of DC upon CD40 ligation
iDC, either non-, mock-or eGFP-electroporated, were cocultured during 48 hours on a monolayer of irradiated (10 4 rad) 3T6 cells and 3T6-hCD40L cells with or without the addition of 1000 U/ml IFNg. Their ability to secrete IL-12 in response to the CD40 crosslinking was evaluated in three replicate cultures. 3T6, 3T6-hCD40L and DC alone were set up as controls. IL-12 p40 and p70 content in the supernatant was determined by ELISA (p40: Biosource, Fleurus, Belgium; p70: Bender Medsystems, Vienna, Austria) according to the manufacturer's instructions.
Flow cytometry analysis
eGFP fluorescence was evaluated on freshly harvested DC resuspended in FACSflow. PI staining also occurred in FACSflow at RT. Other stainings were performed in PBS/BSA/NaN 3 , on ice, and were preceded by blocking of Fc receptors with normal goat serum (Sigma, Bornem, Belgium). To analyze the expression of surface molecules on DC, the following monoclonal antibodies were used: anti-CD14, anti-CD80, anti-CD83, anti-CD86, anti-CD154 (BD PharMingen) and anti-HLA-DR (purified from clone L243) and anti-huNGFR (purified from clone HB8738). All antibodies except anti-HLA-DR and antihuNGFR were phycoerythrin (PE) conjugated. The anti-HLA-DR and anti-huNGFR antibodies were biotinylated and detected through streptavidin-PE binding. Nonreactive isotype-matched antibodies (BD PharMingen) were used as controls. Fluorescence analysis was performed with a FACScalibur flow cytometer (Becton Dickinson, San Jose, CA, USA) using Cell Quest software (Becton Dickinson).
Cryopreservation of DC: freezing medium and thawing conditions
DC were transferred to cryotubes at a concentration of 10 7 cells/ml in human AB serum or autologous plasma with 10% DMSO and 2% glucose and slowly frozen to À801C using a cryo-freezing container (Nalgene cryo, 11C freezing container, rate of cooling À11C/min, Labor Center Nuremberg, Germany). The cryotubes were transferred into liquid nitrogen and stored till use. Dendritic cells were thawed in a 371C waterbath till only small ice crystals were visible. Cold HBSS (Cambrex) was then added dropwise. After pelleting the cells in a precooled centrifuge (41C), the cells were resuspended in X-15/1%HuAB medium or X-15/1%AP medium. Cells were counted with trypan blue after an extra incubation at RT during 15-30 minutes.
Activation of IMP-1-and MelanA-specific T lymphocytes DC electroporated with mRNA were compared to mRNA-pulsed DC (two methods, one according to a protocol described by Gilboa et al and a second protocol mimicking the electroporation conditons) and to peptidepulsed DC for their capacity to activate IMP-1-and MelanA-specific T lymphocytes.
Autologous MACS-enriched T cells (Miltenyi Biotech) were cocultured with the DC (DC:T cell ratio ¼ 1:10) in IMDM (Cambrex) supplemented with 1% heat-inactivated autologous plasma, penicillin-streptomycin and AAG. Induction of IMP-1-specific T cells occurred without the addition of exogenous cytokines, whereas 20 U/ml IL-2 (Chiron, Emeryville, CA, USA) and 10 ng/ml IL-7 (Peprotech) were added for the induction of MelanA-specific T cells.
IMP-1-specific T cells were screened after 7 days of coculture in an IFNg Elispot assay with unloaded or IMP-1-A2 peptide loaded DC.
For the induction of MelanA-specific T cells, cells were restimulated weekly with the same type of stimulator DC as used in the primary stimulation. At 7 days after the third stimulation, T cells were harvested, washed and used in an IFNg Elispot assay with either unloaded T2 cells or MelanA-A2 peptide pulsed T2 cells.
Elispot assay for IFN-g release from CTLs
Microtiter plates (96 wells, MAHA S4510, Millipore) were coated overnight with 5 mg/ml (100 ml/well) anti-IFN-g antibody (Bender Medsystems, BMS228ES Elispot kit) in 100 mM NaHCO 3 , pH 9.6. After extensive washing with RPMI medium, blocking with X-15 supplemented with 10% AB serum for 1 hour and additional washing with RPMI, either 5 Â 10 4 (IMP-1 stimulation) or 1 Â 10 1% heat-inactivated autologous plasma, penicillin-streptomycin and AAG. After 18 hours of culture at 371C, the plates were washed six times with PBS/Tween 0.05% and incubated in 1% Triton for 10 minutes at RT, washed 3 Â with PBS/Tween 0.05% and incubated with biotinylated anti-IFN-g detection antibody (Bender Medsystems) for 3 hours at RT. Plates were washed 6 Â with PBS/Tween 0.05% and alkaline phosphatase stained using streptavidin-ALP solution (Bender Medsystems) and the BCIP-NBT substrate kit (BioRad 170-6432, Nazareth Eke, Belgium) according to the manufacturer's instructions. Plates were washed 6 Â with H 2 O and were air dried. Spots were counted using an AID ELISpot reader (Autoimmun Diagnostika GmbH, Strassberg, Germany). Spots obtained from coculture with unloaded cells were subtracted from the number of spots obtained from coculture with peptide-loaded cells.
Semiquantitative RT-PCR to evaluate gene expression level
The amount of transgene mRNA present in DC electroporated or pulsed with ubi.IMP-1 mRNA was compared. Total RNA was extracted from the cells using the SV Total RNA Isolation System (Promega, Madison, WI, USA). Total RNA (1 mg) was converted into first-strand cDNA using random hexamers and SuperScript II reverse transcriptase according to the manufacturer's recommendations (Superscript First Strand Synthsesis System for RT PCR, Invitrogen, Merelbeke, Belgium). One-tenth of the cDNA was used as the undiluted template in PCR. Serial 10-fold dilutions up to 10 À6 were included. cDNA was amplified in PCR buffer (1 mM Tris-HCl, 50 mM KCl; pH 8.3) containing 2 mM MgCl 2 , 200 mM dNTPs, 1.25 U Taq polymerase (Invitrogen) and 15 pmol of each primer (Eurogentec). The ubi.IMP-1 cDNA was amplified with the ubi-S primer (5 0 GGGCCATGG Nco1 AAATC-TTCGTGAAGACCCTG3 0 ) together with the MP1-AS1 primer (5 0 CCCCTCGAG Xho1 ATACAGTTTAACTGCTT TGT3 0 ) revealing a 530 bp fragment. RNA was tested for DNA contamination by performing the whole procedure without the reverse transcriptase step. As a control for cDNA quality, a b-actin PCR was performed on each serially diluted cDNA (actin1; 5 0 TGCTATCCAGGCTG TGCTAT3 0 and actin2; 5 0 GATGGAGTTGAAGGTA GTTT3 0 ) amplifying a 446 bp fragment. Each PCR cycle consisted of a 941C denaturation step for 30 s, primer annealing at 601C for 30 s followed by primer extension at 721C for 30 s. The first cycle was preceded by a 5 minute denaturation step at 941C. A total of 30 cycles were performed in a Perkin-Elmer GeneAmp PCR system (Perkin Elmer, Zaventem, Belgium). Reactions were performed in a final volume of 25 ml. A volume of 10 ml of the PCR product was then electrophoresed through an ethidium bromide-impregnated agarose gel and visualized by exposure to UV light.
Statistical analysis
Comparison of results obtained for non-, mock-or eGFPelectroporated DC were carried out using the two-tailed unpaired t-test. Differences with Po.01 were considered significant.
Results
Optimization of mRNA electroporation of human dendritic cells
In order to optimize the transfection of DC by electroporation with in vitro synthesized mRNA, we investigated the use of different media during the electroporation process. Owing to the instability of mRNA, the electroporation has to be performed in serum-free conditions to prevent degradation of the mRNA. However, we found that it was critical that the cells are transferred immediately after electroporation (within 30 s) to serumcontaining culture medium in order to prevent excessive cell death.
The electroporation was initially performed in X-15 medium without serum, but since a significant degree of cell death was observed, the use of Optimix electroporation buffer was tested. This Optimix electroporation buffer mimics the cytoplasmic environment of the cells and contains compounds that facilitate rapid resealing of the pores. Both the electroporation efficiency and cell viability were higher when this buffer was used. Electroporation efficiency was 59718 and 7679% for electroporation in X-15 (n ¼ 24) and Optimix (n ¼ 63) respectively (Po.0001). The percentage of viable cells was 59713 and 81711% for electroporation in X-15 (n ¼ 24) and Optimix (n ¼ 63) respectively (P o .0001). Electroporation in the presence of X-15 also had a negative effect on the maturation process. The percentage of both CD80-and CD83-expressing cells was dramatically reduced (45 and 21% respectively, in X-15, compared to 68 and 51% respectively in Optimix; data not shown) as well as the mean fluorescence intensity (MFI) of the CD86 and HLA-DR expression (a decrease of 50%; data not shown). The percentage of CD86-and HLA-DR-expressing cells remained the same in both electroporation media.
To obtain optimal electroporation conditions, we diluted the amount of mRNA for an equal number of DC in a fixed volume of 200 ml. We used 5, 10, 20, 40 or 50 mg of eGFP mRNA to electroporate 4 Â 10 6 DC. The electroporation efficiency was not affected by using different amounts of mRNA, but the MFI of eGFP decreased with lower amounts of mRNA (Fig 1) . When the amount of mRNA was kept constant at 20 mg while varying the cell number (4 Â 10 6 or 8 Â 10 6 ) in 200 ml, the electroporation efficiency and the MFI remained the same (data not shown). The use of 12 Â 10 6 DC in the same electroporation conditions required an amount of 30 mg of mRNA to obtain an equal MFI.
Furthermore, we investigated whether the contaminating T and B cells in the DC cultures influenced the efficient electroporation of the DC. We electroporated either DC with contaminating cells (mostly B lymphomRNA-electroporated DC in immunotherapy S Tuyaerts et al cytes) or DC purified by magnetic depletion of B and T lymphocytes, and subsequently compared the eGFP expression in the gated DC population. From these experiments, we could conclude that the contaminating cells have no negative effect on the electroporation efficiency of DC (data not shown). The contaminating lymphocytes were not transfected and did not express the eGFP protein.
Electroporation efficiency and duration of the transgene expression were assessed by means of eGFP and WNGFR electroporation. Both the percentage of electroporated cells and the duration of transgene expression were equal when transfected with either eGFP-or WNGFR-encoding mRNA (Fig 2) . We observed that a high percentage of DC were still positive 72 hours postelectroporation.
One of the functional characteristics of mature DC is their high allo-stimulatory capacity. In order to analyze their capacity to induce a proliferative response of allogeneic T lymphocytes, monocyte-derived DC were electroporated at day 6, matured for 24 hours and used as stimulator cells. At day 7, graded numbers of DC (non-, mock-and eGFP-electroporated) were cocultured in triplicate with allogeneic T lymphocytes at different responder:stimulator (R:S) ratios.
We observed no significant difference in the allostimulatory capacity between non-, mock-and eGFPelectroporated DC (data not shown). Even at high R:S ratios (900:1), we observed a strong stimulatory capacity to allogeneic T cells.
IL-12 plays a central role in the induction of a naive antigen-specific T-cell response. IL-12 is secreted by DC after CD40 ligation. In order to check the capacity of electroporated DC to secrete IL-12, DC were electroporated on day 6 of the culture and subsequently cocultured with hCD40L-expressing fibroblasts with or without IFNg for 48 hours. IL-12 p40 and p70 released by these stimulated DC were quantified by ELISA. We observed a decrease in the amount of IL-12 produced by mock-and eGFP-electroporated DC, compared to nonelectroporated DC. Although eGFP-electroporated DC produced less IL-12, the amount is still significantly higher than that produced by unstimulated DC (Fig 3a  and b) .
Adjustments in view of clinical trials
In view of future clinical trials, where large amounts of iDC obtained from leukaphereses (approximately 400 Â 10 6 ) have to be electroporated, we decided to investigate whether we could upscale the electroporation. Therefore, we compared the electroporation of 12 Â 10 6 cells with 30 mg mRNA in 200 ml with the electroporation of 50 Â 10 6 cells with 120 mg mRNA in 600 ml. The electroporation occurred in the same type of cuvette, so that only the capacitance had to be changed proportionally to the volume (from 150 to 450 mF). As shown in Table 1 , the electroporation of 50 Â 10 6 iDC did not result in a decreased viability, purity or relative yield of the mDC preparation, compared to the electroporation of 12 Â 10 6 iDC. The electroporation efficiency was also not affected when 50 Â 10 6 cells instead of 12 Â 10 6 cells were electroporated (data not shown).
For their use in cancer immunotherapy, it is indispensible to perform a freezing step of the mature, electroporated DC. DC were electroporated on day 6, matured for 24 hours and frozen. After thawing, transgene expression, viability, immunophenotype and mRNA-electroporated DC in immunotherapy S Tuyaerts et al allo-stimulatory capacity were assessed. We found no difference in the viability of fresh and frozen/thawed DC ( Table 2) . Fresh DC revealed viabilities of 94.574, 89.2576 and 84.7574% respectively for non-, mockand eGFP-electroporated DC. Frozen/thawed DC showed viabilities of 93.2572, 92.2575 and 82.575% respectively for non-, mock-and eGFP-electroporated DC. A minor reduction in the transgene expression was observed in the frozen/thawed DC ( Table 2 , P ¼ .15). This phenomenon could be due to the fact that the electroporation efficiency for the frozen/thawed cells was assessed 24 hours later (48 hours postelectroporation) due to the included freezing cycle, when compared to their fresh counterparts (which were analyzed 24 hours postelectroporation). Phenotypic analysis of the frozen/ thawed DC showed no significant difference compared to fresh DC (Fig 4) . The frozen/thawed mature, electroporated DC showed an equal capacity to stimulate allogeneic T cells compared to their nonelectroporated counterparts (data not shown).
Activation of anti-influenza memory T lymphocytes by fresh and cryopreserved IMP-1 mRNA electroporated DC
The antigen presenting capacity of mRNA-electroporated DC was analyzed by the induction of an antigen-specific memory T-cell response. Therefore, DC were electroporated with IMP-1 mRNA at day 6 of culture and subsequently matured for 24 hours. The mature, IMP-1-electroporated DC were then cocultured for 7 days with purified autologous CD8 + T cells without the addition of exogenous cytokines. Alternatively, the mature, IMP-1-electroporated DC were frozen and thawed before coculture with T cells.
The expansion of IMP-1-specific CD8 + T cells was measured by the appearance of IFN-g-secreting lymphocytes. We restimulated the IMP-1-stimulated T cells overnight with either nonloaded DC or DC loaded with IMP-1-A2 peptide. In these cocultures, the activation of IMP-1-specific T-cell clones was visualized at a single Tcell level using the ELISPOT technique for IFN-g secretion (Fig 5a and b) . We observed an efficient Immature, day 6 DC were electroporated either at 12 Â 10 6 or 50 Â 10 6 per electroporation and cultured overnight in the presence of GM-CSF and IL-4. On day 7, the maturation stimulus was added for 24 hours, after which the mDC were harvested and analyzed by trypan blue staining to determine the viability, purity and relative yield of the mDC. Data are expressed as mean of three independent experiments7SD. Immature, day 6 DC were either non-, mock-or eGFP-electroporated and matured for 24 hours. Viability was assessed by trypan blue staining and eGFP expression was measured by flow cytometry when applicable. Subsequently, the mDC were frozen/thawed and viability was assessed again 30 minutes after thawing. Thawed DC were further cultured for 24 hours in X-15/1%AB after which the eGFP expression was measured by flow cytometry. P-values for the viability of DC before and after thawing were 0.66 for nonelectroporated DC, 0.52 for mock-electroporated DC and 0.57 for eGFP-electroporated DC. The P-value for eGFP expression by DC before and after thawing was 0.15. Data are expressed as mean of four independent experiments7SD. NA, not applicable.
mRNA-electroporated DC in immunotherapy S Tuyaerts et al stimulation of IMP-1-specific memory T lymphocytes by both fresh (Fig 5a) and frozen/thawed (Fig 5b) IMP-1-electroporated DC. We could thus conclude that freezing and thawing of mature, electroporated DC did not have an influence on their capacity to induce an antigenspecific memory T-cell response.
Correlation between the expression level of the transgene and the antigen presentation capacity of IMP-1 mRNA electroporated DC
Since we observed large differences in transgene expression levels between passive mRNA pulsing of DC compared to mRNA electroporation of DC, we investigated whether this reflects a different T-cell stimulatory capacity. Therefore, we compared mDC passively pulsed with IMP-1 mRNA by two methods, one according to a published protocol and one mimicking the mRNA concentration and cell density during the electroporation. These DC were compared for the amount of the transgene mRNA in the DC by RT-PCR (Fig 6a) and for their capacity to induce IMP-1-specific CTL (Fig 6b) . DC were either electroporated or pulsed with IMP-1-encoding mRNA at day 6 and matured. After 24 hours, mDC were harvested and cocultured with autologous CD8 + T cells (ratio DC:T ¼ 1:10). Aliquots of the mDC (electroporated or pulsed with mRNA) were also snapfrozen for RT-PCR analysis. Nonelectroporated DC were included as a negative control. At 7 days after the initiation of coculture, T cells were restimulated with either IMP-1-A2 (GILGFVFTL; amino acids 58-66) peptide loaded DC or nonpulsed DC, and IMP-1-specific T cells were visualized using the IFNg-ELISPOT technique.
In Figure 6a , we show that IMP-1 mRNA pulsed DC (method 1 according to Gilboa et al) did not lead to a detectable transgene mRNA level 24 hours after pulsing. However, we observed a faint band at dilution 10 À1 with DC loaded with mRNA according to method 2 (mimicking the electroporation conditions) 24 hours after pulsing and we could still detect the transgene at dilution 10
À3
with IMP-1-electroporated DC 24 hours after electroporation. The IFNg-ELISPOT assays indicate that IMP-1-pulsed DC according to method 1 induced the weakest CTL response, followed by IMP-1-pulsed DC (method 2) and IMP-1-electroporated DC (Fig 6b) . 
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We conclude that the level of IMP-1 mRNA expression correlates with the capacity of the DC to induce an IMP-1-specific CD8 + T-cell response. These results also show that mRNA-electroporated DC are better initiators of an IMP-1-specific T-cell response, when compared to mRNA-pulsed DC.
Activation of naive T lymphocytes against the MelanA/ MART-1 tumor differentiation antigen
In order to check if mRNA-electroporated DC are capable of initiating a T-cell response against a tumor antigen, we compared MelanA mRNA pulsed and electroporated DC with MelanA-A2 peptide loaded DC for their capacity to induce CTL. DC were either electroporated or pulsed (two methods, the first according to a protocol described by Gilboa et al and the second mimicking the electroporation conditions) with MelanA-encoding mRNA at day 6 and matured. After 24 hours, mDC were harvested and cocultured with autologous T cells (ratio DC:T ¼ 1:10). Alternatively, day 6 DC were matured for 24 hours and subsequently pulsed with MelanA-A2 peptide before use. Cells were restimulated weekly at the same ratio with the same type of DC as for the primary stimulation. At 1 week after the third stimulation, T cells were restimulated with either unloaded or MelanA-A2 peptide loaded T2 cells, and IFNg-secreting cells were visualized using the IFNg-ELISPOT technique.
As shown in Figure 7 , we observed a better induction of a MelanA-specific CTL response by MelanA-A2 peptide pulsed DC, compared to MelanA mRNA electroporated DC. It has been reported that the MelanA-A2 epitope is immunoproteasome dependent. 41, 42 mDC predominantly contain the immunoproteasome which destroys the MelanA-A2 epitope and this will lead to a lower amount of MelanA-A2 peptides produced in electroporated DC and a less efficient stimulation of MelanA-A2-specific T cells. However, these results also show that MelanA mRNA electroporated DC are more potent in inducing MelanA-A2-specific CTLs compared to passively MelanA mRNA pulsed DC (two methods). This is consistent with the results obtained for the activation of anti-influenza CTL.
Discussion
Cancer immunotherapy is considered as a potentially powerful approach to eradicate residual tumor cells that Figure 6 Correlation between transgene expression level and antigen presentation capacity of mRNA-pulsed or -electroporated DC. (a) Transgene expression level in mRNA-pulsed or -electroporated DC. DC were either nonelectroporated, IMP-1-electroporated or IMP-1-loaded (two protocols, one according to a method described by Gilboa et al and a second mimicking the electroporation conditions) and subsequently matured for 24 hours. These mDC were used for RNA isolation and subsequent cDNA synthesis. The cDNA quality was checked by PCR for -actin (data not shown), and subsequently a semiquantitative PCR was performed to determine the expression level of the transgene. The data are representative of two independent experiments. (b) Antigen presentation capacity of mRNA-pulsed or -electroporated DC. DC were either nonelectroporated, IMP-1-electroporated or IMP-1-loaded (two protocols) and matured for 24 hours. The mature, IMP-1-electroporated or IMP-1-loaded DC were then cocultured for 7 days with purified autologous CD8 + T cells without the addition of exogenous cytokines. Nonelectroporated DC were included as a negative control. We restimulated the IMP-1-stimulated T cells overnight with either nonloaded DC or DC loaded with IMP-1.A2 peptide. In these cocultures, the activation of IMP-1-specific T-cell clones was visualized using the ELISPOT technique for IFN-g secretion. The data are representative of two independent experiments. Figure 7 Activation of MelanA-specific CTL. DC were either MelanA-A2 peptide pulsed, MelanA mRNA electroporated or passively pulsed with mRNA (two protocols) and matured for 24 hours. These mDC were then used for coculture with purified autologous T cells (ratio DC:T ¼ 1:10) in the presence of IL-2 and IL-7. Cocultures were stimulated weekly with cryopreserved DC (either peptide-loaded, mRNA-electroporated or mRNA-pulsed). After three rounds of stimulation, T cells were harvested and restimulated overnight with either unloaded or MelanA.A2 peptide loaded T2 cells. In these cocultures, the activation of MelanA-specific T-cell clones was visualized using the ELISPOT technique for IFN-g secretion. The data are representative of two independent experiments. mRNA-electroporated DC in immunotherapy S Tuyaerts et al remain in the body of the patient after conventional treatment. Genetically modified DC are ideal candidates for the induction of a tumor-specific immune response. Until now, viral gene delivery systems have been very effective for transducing human dendritic cells. However, the use of these viral vectors is hampered by safety concerns. [24] [25] [26] [27] Recently, mRNA electroporation of human monocyte-derived DC was described as a very efficient tool, without the need for viral vectors. 34, [36] [37] [38] Here, we further expand on the method of mRNA electroporation of human monocyte-derived DC. This procedure is considered to be very safe, because the mRNA has a short half-life in the cells, and is not integrated into the genome of the cells. 32 In contrast to the use of viral vectors, no immunogenic viral proteins are introduced, which could result in an overwhelming antiviral immune response.
We show that electroporation efficiencies of human monocyte-derived DC of 70-80% can be easily achieved, without a major impact on cell viability. The electroporated DC retain the capacity to mature and are strong inducers of an allogeneic T-cell response. The capacity of electroporated DC to secrete IL-12 after CD40 ligation is slightly reduced when compared to their normal counterparts. This diminution of IL-12 secretion is also observed with murine mRNA electroporated DC (Van Meirvenne et al, unpublished results).
We also compared the transgene mRNA level in the DC after mRNA electroporation or mRNA loading based on the spontaneous uptake by iDC. These results showed a much higher expression level of the transgene mRNA in mRNA-electroporated DC compared to the passively pulsed DC. This difference is also reflected in their capacity to induce an antigen-specific T-cell response: mRNA-electroporated DC were better at inducing IMP-1-specific T cells, compared to mRNApulsed DC. Furthermore, we demonstrate that mRNAelectroporated DC can induce a CTL response against the melanoma differentiation antigen MelanA/MART-1. As observed for the activation of anti-influenza-specific CTL, we also show that mRNA-electroporated DC are more potent at inducing MelanA-specific CTL, compared to mRNA-pulsed DC. Gilboa and co-workers have previously reported the efficient induction of anticancer immune reponses in mice and humans by using mRNApulsed DC. 28, 33, 43 Based on these observations and the results described by Van Meirvenne et al, 44 we are convinced that the use of mRNA-electroporated DC could further augment these immune responses.
In view of clinical trials where large numbers of DC have to be electroporated, we have upscaled the electroporation protocol to avoid contaminations due to repeated manipulations. Electroporation of 50 Â 10 6 DC has no detrimental effects on viability and electroporation efficiency. Furthermore, electroporated and matured DC could be efficiently frozen/thawed, without any impact on viability, phenotype or ability to stimulate T cells. The possibility to charge the DC with TAA-encoding mRNA before storage allows for an extensive quality control (viability, phenotype, allo-stimulatory capacity, transgene expression and sterility) before administration to the patient.
Currently, most clinical studies in cancer patients are carried out with peptide-pulsed DC. However, this approach has the drawback that only patients with a certain HLA type can be included in the study and that only responses against (known) epitopes can be induced by the vaccine. Vaccination with mRNA-electroporated DC could overcome these problems, because various epitopes of the TAA (also those not yet identified) will be presented on the different HLA molecules of the patient. Furthermore, results obtained by Bonehill et al (manuscript submitted to Cancer Research) have shown that mRNA electroporation leads to a prolonged and stable presentation of a TAA epitope, compared to peptidepulsed DC where presentation was rapidly lost. Another advantage of mRNA-electroporated DC is that we can incorporate targeting signals into a tumor-associated antigen, in order to obtain both CD4 + and CD8 + antigen-specific T-cell responses. 44 Altogether, we conclude that mRNA-electroporated DC are more potent initiators of antigen-specific T-cell responses than mRNA-pulsed DC. We postulate that mRNA-electroporated DC actually lead to an improved vaccine, compared to peptide-pulsed DC and even to mRNA-pulsed DC.
